Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Combined GS-4774 and Tenofovir Therapy can Improve HBV-Specific T-Cell Responses in Patients with Chronic Hepatitis.

Carolina Boni,Harry L A Janssen,Marzia Rossi,Seung Kew Yoon,Andrea Vecchi,Valeria Barili,Eric M Yoshida,Huy Trinh,Timothy C Rodell,Diletta Laccabue,Arianna Alfieri,Federica Brillo,Paola Fisicaro,Greta Acerbi,Giuseppe Pedrazzi,Pietro Andreone,Carmela Cursaro, Marzia Margotti,Rosanna Santoro,Valeria Piazzolla,Maurizia R Brunetto,Barbara Coco,Daniela Cavallone,Yang Zhao,Adarsh Joshi,Jacky Woo,Audrey H Lau,Anuj Gaggar,G Mani Subramanian,Benedetta Massetto,Scott Fung,Sang Hoon Ahn,Xiaoli Ma,Alessandra Mangia,Carlo Ferrari

Gastroenterology（2019）

Cited 98|Views5
No score
Abstract
In a phase 2 study of patients with chronic HBV infection given TDF with or without GS-4774, we found that vaccination can increase production of IFNG, TNF, and IL2 by CD8+ T cells exposed to antigenic peptides, with little effect on CD4+ T cells. Although GS-4774 did not reduce levels of HBsAg in patients, its strong immune stimulatory effect on CD8+ T cells might be used in combination with other antiviral agents to boost the anti-virus immune response. Clinicaltrials.gov no: NCT02174276.
More
Translated text
Key words
CHB,Treg Cell,Tolerance,Immunotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined